Completing data — refresh the page later to see the latest
1402837-78-8OC1CCC([C@H](O)C[C@H]2c3c(F)cccc3-c3cncn32)CC1YGACXVRLDHEXKY-YYJRJVKZNA-NNavoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).
1402837-78-8UsesNavoximod (GDC-0919; NLG-919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
CHEMBL4530496